Quick Answer
Boundless Bio, Inc. reported Stockholders Equity of $98.65 million for the year ending 2025.
- Boundless Bio, Inc. showed a decrease of -34.5% in Stockholders Equity from 2024 to 2025.
- This data is from Boundless Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$141.18 million | Q2 2024: $179.25 million | Q3 2024: $165.08 million | Q1 2025: $136.59 million | Q2 2025: $122.69 million | Q3 2025: $110.17 million.
- Over the full 3 years of available data (2023 to 2025), Boundless Bio, Inc.'s Stockholders Equity has grown by 177.6%.
- Historical annual values: Fiscal year 2025: $98.65 million | Fiscal year 2024: $150.64 million | Fiscal year 2023: -$127.08 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: